{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:11:08Z","timestamp":1778134268290,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Japanese Society of Implantable Port Assisted Treatment"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bevacizumab (BEV) is commonly used to treat unresectable or metastatic colorectal cancer; however, it is associated with delayed wound healing. This study aimed to assess whether administration of BEV within 14\u00a0days after central venous (CV) port placement was associated with an increased incidence of delayed wound healing complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with unresectable or metastatic colorectal cancer who underwent CV port placement between January 2017 and January 2023. The primary outcome was the incidence of wound-healing complications within 90\u00a0days. The incidence of complications was examined in 29 patients who received BEV within 8\u00a0weeks prior to CV port placement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data on 264 matched patient pairs, selected from 778 eligible patients, were included in the analysis. Wound healing complications occurred in 4\/264 patients (1.5%; 95% confidence interval [CI], 0.4%\u20134.0%) in the BEV group and 3\/264 patients (1.1%; 95% CI, 0.2%\u20133.4%) in the non-BEV group, a nonsignificant difference (P\u00a0&amp;gt;\u00a0.99). Additionally, no wound-healing events were observed among the 29 patients who received BEV before CV port placement; however, this finding should be interpreted with caution because of the limited sample size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of BEV before and after CV port placement does not significantly increase the risk of delayed wound healing complications. These findings suggest that the risk of delayed wound healing associated with peri\u2013CV port administration of BEV appears to be low in this specific clinical setting; however, this should be interpreted with caution and does not constitute definitive proof of safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag006","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:51:38Z","timestamp":1767963098000},"page":"546-552","source":"Crossref","is-referenced-by-count":0,"title":["Association between bevacizumab administration and delayed wound healing complications before and after central venous port placement in patients with colorectal cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4422-6604","authenticated-orcid":false,"given":"Kohei","family":"Takura","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]},{"name":"Division of Cancer Medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-1419","authenticated-orcid":false,"given":"Hidekazu","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Tanishima","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakuhei","family":"Nakama","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Itou","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-3826","authenticated-orcid":false,"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology\/Interventional Radiology Center, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026050701222462100_ref1","article-title":"NCCN Clinical Practice Guidelines in Oncology: Colon Cancer","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"2026050701222462100_ref2","author":"National Cancer Institute Statistics","year":"2023"},{"key":"2026050701222462100_ref3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050701222462100_ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2026050701222462100_ref5","article-title":"NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. version 2.2024","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"2026050701222462100_ref6","article-title":"NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. version 2.2024","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"2026050701222462100_ref7","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026050701222462100_ref8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"2026050701222462100_ref9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026050701222462100_ref10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026050701222462100_ref11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026050701222462100_ref12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14740338.5.4.553","article-title":"Incidence and management of bevacizumab-related toxicities in colorectal cancer","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"2026050701222462100_ref13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jvir.2009.01.022","article-title":"Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy","volume":"20","author":"Zawacki","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"2026050701222462100_ref14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.25573","article-title":"Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement","volume":"117","author":"Erinjeri","year":"2011","journal-title":"Cancer"},{"key":"2026050701222462100_ref15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00520-014-2466-y","article-title":"Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis","volume":"23","author":"Berardi","year":"2015","journal-title":"Support Care Cancer"},{"key":"2026050701222462100_ref16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/CAD.0b013e32833a5c51","article-title":"Indwelling central venous access port insertion during bevacizumab-based therapy","volume":"21","author":"Grenader","year":"2010","journal-title":"Anticancer Drugs"},{"key":"2026050701222462100_ref17","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/cancers15082264","article-title":"Safety of early bevacizumab administration after central venous port placement for patients with colorectal cancer","volume":"15","author":"Shigyo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026050701222462100_ref18","volume-title":"Centers for Disease Control and Prevention. Surgical Site Infection Event (SSI) 2025","author":"National Healthcare Safety Network"},{"key":"2026050701222462100_ref19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"2026050701222462100_ref20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13244-019-0770-2","article-title":"Complications of central venous port systems: a pictorial review","volume":"10","author":"Machat","year":"2019","journal-title":"Insights Imaging"},{"key":"2026050701222462100_ref21","first-page":"9","article-title":"Evaluation of complications of totally implantable central venous port systems","volume":"24","author":"Kim","year":"2019","journal-title":"Eur J Med Res"},{"key":"2026050701222462100_ref22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jjco\/hym118","article-title":"Central venous access port-related complications in outpatient chemotherapy for colorectal cancer","volume":"37","author":"Inaba","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"2026050701222462100_ref23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CAD.0b013e3282f2c063","article-title":"Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series","volume":"19","author":"Almhanna","year":"2008","journal-title":"Anticancer Drugs"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/546\/66610690\/hyag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/546\/66610690\/hyag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:22:28Z","timestamp":1778131348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/5\/546\/8443112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag006","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,28]]}}}